Article
PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.
Experimental neurology - 1 Sept 2017
Hsu Wei-Chun J, Wildburger Norelle C, Haidacher Sigmund J, Nenov Miroslav N, Folorunso Oluwarotimi, Singh Aditya K, Chesson Brent C, Franklin Whitney F, Cortez Ibdanelo, Sadygov Rovshan G, Dineley Kelly T, Rudra Jay S, Taglialatela Giulio, Lichti Cheryl F, Denner Larry, Laezza Fernanda
Abstract excerpt
BACKGROUND: Cognitive impairment in humans with Alzheimer's disease (AD) and in animal models of Aβ-pathology can be ameliorated by treatments with the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARγ) agonists, such as rosiglitazone (RSG). Previously, we demonstrated that in the Tg2576 animal model of AD, RSG treatment rescued cognitive deficits and reduced aberrant activity of granule...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.